Agilent - Breakthroughs in Immunotherapy- 2019 - 34

Application Note

Multifunctional Potency Assays
for Cancer Immunotherapy
ACEA Biosciences Describes New Tools to Quantify Tumor
Cell Killing Enhanced by Bispecific T-cell Engagers
By Lauren Jachimowicz, PhD, Aimee Chiavario, Peifang Ye,
Garret Guenther, PhD, Kenneth Chan, PhD, Jeff Shurong Xue, PhD

C

ancer immunotherapy is increasingly being evaluated as an approach to cancer treatment by
harnessing the immune system to attack cancer cells. Both the adaptive and innate arms of
the immune system play a pivotal role in a host's defense against tumors.

CD8+ cytotoxic T lymphocytes (CTLs), which constitute a major component of the adaptive immune
response, directly eliminate tumor cells by releasing cytolytic proteins such as granzymes, perforin,
and granulysin, in addition to producing multiple cytokines. The ability to correlate T-cell biomarker
expression/secretion with target cell killing is critical for tumor immunology studies.
Moving this research from the bench to the clinic is critically important, but reliable tools are needed
to design in vitro assays that closely mimic activity in vivo. In this study, we use an impedance-based
technology in combination with a bead-based multiplex flow cytometry assay to evaluate both the
target and effector cells in a T-cell-mediated B-cell-killing potency assay (Figure 1). Real-time cell
analysis (RTCA) technology with ACEA Biosciences' xCELLigence® system provides us with a continuous readout of target cell viability, while flow cytometry enables the study of T-cell activation and

34

| GENengnews.com

Additional Info

Download the
xCELLigence
RTCA Cancer
Immunotherapy
Handbook:

https://go.aceabio.com/GENimmunotherapyhandbook http://www.GENengnews.com

Agilent - Breakthroughs in Immunotherapy- 2019

Table of Contents for the Digital Edition of Agilent - Breakthroughs in Immunotherapy- 2019